Ocular Therapeutix (OCUL) continues to draw attention after recent share price moves, with the stock last closing at $8.94. Investors are evaluating its clinical pipeline, hydrogel technology and mixed short term return profile.

While Ocular Therapeutix shares are currently at $8.94 and have risen over the past week, the stock is still down year to date, even though the 1 year and 3 year total shareholder returns are positive. This may indicate shifting sentiment around its risk and growth profile.

If you are looking beyond Ocular Therapeutix for other opportunities in healthcare and biotech, this could be a good moment to see what stands out in 40 healthcare AI stocks

Ocular Therapeutix stock trades at a steep discount to the latest analyst price target and sits well below its recent 1 year total return, so is the market overlooking its hydrogel pipeline or already pricing in future growth?

Most Popular Narrative: 65.6% Undervalued

Compared with Ocular Therapeutix stock at $8.94, the most followed narrative points to a fair value of $26, highlighting a wide gap that hinges on AXPAXLI and the hydrogel platform.

The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6 to 12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.

Want to see what sits behind that confidence in Ocular Therapeutix? The narrative leans on rapid revenue expansion, shifting margins and a future earnings multiple more often associated with fast growing sectors. The assumptions are bold. The calculations are detailed. The full story connects these moving parts into that $26 fair value call.

Result: Fair Value of $26 (UNDERVALUED)

However, this Ocular Therapeutix story also leans heavily on AXPAXLI trial success and regulatory timing. Any setback or delay could quickly challenge that $26 fair value case.

Another View On Ocular Therapeutix Valuation

The first narrative for Ocular Therapeutix leans on a fair value of $26 per share, but the SWS DCF model points to a future cash flow value of $92.45 per share at a current price of $8.94. That is a very large gap. Is this an opening or just higher risk being ignored?

Next Steps

With sentiment split between the upside case and the risks highlighted in this Ocular Therapeutix story, it makes sense to review the underlying data yourself and decide how comfortable you are with the trade off between potential and uncertainty, starting with the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Ocular Therapeutix?

If Ocular Therapeutix has caught your attention, do not stop there. Broaden your watchlist with other clear, data driven ideas that might suit your style.

• Target resilient cash generators with the solid balance sheet and fundamentals stocks screener (48 results) to see companies that pair financial strength with consistent fundamentals.
• Pursue potential mispricings through the screener containing 20 high quality undiscovered gems and spot quality businesses that are still off most investors' radar.
• Prioritise sleep at night investing by scanning the 67 resilient stocks with low risk scores and focus on companies with lower overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.